- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 223 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 323 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,436 | +1,39 % | Sangamo Therapeutics falls on CFO retirement | ||
| IMMATICS | 4,920 | -0,81 % | Immatics Announces Second Quarter 2025 Financial Results and Business Update | Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated... ► Artikel lesen | |
| ALDEYRA | 4,639 | +1,09 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MEDIFAST | 11,780 | -1,13 % | Medifast Bolsters Growth Through Health & Wellness Solutions | ||
| PHARMING | 1,221 | -0,33 % | Pharming Group N.V.: Pharming Group promoted to the Euronext AMX index | Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,120 | +2,24 % | Strategiewechsel bei Coherus: Voller Fokus auf Immunonkologie | ||
| ORUKA THERAPEUTICS | 13,500 | +3,05 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented at EADV in September 2025 ORKA-002 Phase... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 2,420 | -0,82 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update | Entered into secured credit agreement with Innoviva for $15 million maturing in 2029
Announced positive topline results from the Phase 1b /2a diSArm trial for AP-SA02
... ► Artikel lesen | |
| INNOVIVA | 17,200 | +4,24 % | Innoviva Specialty Therapeutics, Inc.: FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 | FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new... ► Artikel lesen | |
| DBV TECHNOLOGIES | 1,638 | +1,24 % | DBV Technologies S.A.: DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq | Châtillon, France, September 5, 2025
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT)... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 1,050 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update | Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025
NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 8,915 | -1,71 % | SIGA Technologies - A solid quarter for topline growth | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
| LIQUIDIA | 21,760 | -1,72 % | Liquidia Technologies, Inc.: Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update | YUTREPIA surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 13,700 | +3,01 % | Syndax resumed with Buy at Stifel on newly launched drugs | ||
| MATINAS BIOPHARMA | 1,790 | 0,00 % | Matinas BioPharma Holdings, Inc. - 8-K, Current Report |
Das Unternehmen MOLECURE SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,134 (+9,20 %) liegt der Kurs bei 1,590 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.